Edition:
United Kingdom

MiMedx Group Inc (MDXG.OQ)

MDXG.OQ on NASDAQ Stock Exchange Capital Market

3.22USD
16 Jul 2018
Change (% chg)

$-0.15 (-4.45%)
Prev Close
$3.37
Open
$3.36
Day's High
$3.50
Day's Low
$3.20
Volume
636,038
Avg. Vol
842,970
52-wk High
$18.24
52-wk Low
$3.01

Chart for

About

MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company's Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical,... (more)

Overall

Beta: 0.89
Market Cap(Mil.): $1,364.26
Shares Outstanding(Mil.): 112.47
Dividend: --
Yield (%): --

Financials

  MDXG.OQ Industry Sector
P/E (TTM): 65.63 32.18 32.76
EPS (TTM): 0.18 -- --
ROI: 14.78 13.91 14.61
ROE: 15.77 16.75 16.34

MiMedx to restate financial statements, replaces CFO

Biotech firm MiMedx Group Inc replaced its chief financial officer on Thursday and said it would restate at least five years of financial statements following an internal investigation into sales and distribution practices, sending shares down as much as 30 percent.

07 Jun 2018

UPDATE 3-MiMedx to restate financial statements, replaces CFO

* Co restates statements from fiscal 2012-2016, 3 quarters in 2017

07 Jun 2018

MiMedx to restate financial statements, appoints interim CFO

June 7 Biotech MiMedx Group Inc said on Thursday it plans to restate certain financial statements and appointed Edward Borkowski as its interim chief financial officer.

07 Jun 2018

BRIEF-Mimedx Comments On Matters Related To Former Va Employees

* MIMEDX GROUP INC - COMMENTED ON INDICTMENT FILED IN COURT AGAINST INDIVIDUALS PREVIOUSLY EMPLOYED BY DEPARTMENT OF VETERANS AFFAIRS

10 May 2018

U.S. indicts three veterans healthcare providers over MiMedx payments

Three healthcare providers with the U.S. Department of Veterans Affairs were indicted on charges they excessively used biotech MiMedx Group Inc's products on patients after accepting meals, trips and gratuities from the company.

09 May 2018

U.S. indicts three veterans healthcare providers over MiMedx payments

May 9 Three healthcare providers with the U.S. Department of Veterans Affairs were indicted on charges they excessively used biotech MiMedx Group Inc's products on patients after accepting meals, trips and gratuities from the company.

09 May 2018

BRIEF-MiMedx Sees Q2 Revenue $96 Million To $98 Million

* MIMEDX REPORTS UNREVIEWED FIRST QUARTER REVENUE EXCEEDED UPPER END OF ITS GUIDANCE

26 Apr 2018

BRIEF-MiMedx Enrolls First Patient In Its Phase 2B Clinical Trial Of Amniofix® Injectable For Treatment Of Osteoarthritis Of The Knee

* MIMEDX ENROLLS FIRST PATIENT IN ITS PHASE 2B CLINICAL TRIAL OF RMAT DESIGNATED AMNIOFIX® INJECTABLE FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE Source text for Eikon: Further company coverage:

28 Mar 2018

BRIEF-Mimedx Reports Positive Results From Phase 2B Clinical Trial Of Amniofix Injectable

* MIMEDX REPORTS POSITIVE PAIN AND FOOT FUNCTION RESULTS FROM PHASE 2B CLINICAL TRIAL OF AMNIOFIX® INJECTABLE IN THE TREATMENT OF PLANTAR FASCIITIS

26 Mar 2018

BRIEF-MiMedx Says "Confident" in Q1 Rev Guidance, Discloses DoJ Investigation

* MIMEDX ANNOUNCES EXPECTATION TO EXCEED THE $92 MILLION TOP END OF FIRST QUARTER REVENUE GUIDANCE

15 Mar 2018

Competitors

  Price Chg
Shire PLC (SHP.L) 4,324.00 --
Shire PLC (3159084.L) -- --
Smith & Nephew plc (SN.L) 1,332.00 --

Earnings vs. Estimates